2076975 2077203
최종편집 2024-06-15 06:02 (토)
HumasisㆍSeegene quarterly operating profit exceeded KRW 200 billion, ↑KRW 100 billion for Samsung BiologicsㆍCelltrion
상태바
HumasisㆍSeegene quarterly operating profit exceeded KRW 200 billion, ↑KRW 100 billion for Samsung BiologicsㆍCelltrion
  • Hyeokgi Lee, Newsmp
  • 승인 2022.05.19 17:30
  • 댓글 0
이 기사를 공유합니다

Operating profit of KRW 1.2392 trillion for 149 pharmaceutical and bio companies in Q1
Four companies with the KRW 100 billion mark reached KRW 721.5 billion… 54 companies     are in the red

[Newsmp] In the first quarter, 149 listed pharmaceutical and bio companies (manufacturing industry of medical materials and pharmaceuticals) whose closing accounts are in December achieved operating profits of KRW 1.2392 trillion.

In particular, the operating profit of four bio companies, including Humasis, Seegene, Samsung Biologics, and Celltrion, exceeded KRW 100 billion, and the combined operating profit of these companies reached KRW 721.5 billion.

95 out of 149 listed pharmaceutical and bio companies posted a surplus and 54 recorded a deficit in the first quarter, according to FnGuide.

Among them, 25 pharmaceutical and bio companies achieved a surplus of more than KRW 10 billion, and their combined operating profit reached KRW 1.18 trillion.

The combined operating profit of 70 companies with a surplus of less than KRW 10 billion was KRW 242.2 billion, with an average surplus of 3.5 billion per company.

In addition, the combined operating loss of 54 companies in the red was KRW 19.3 billion, with an average loss of KRW 3.5 billion per company.

Of the 25 pharmaceutical and bio companies that achieved an operating profit of more than KRW 10 billion, 4 bio companies outperformed others.

Humasis, which supplied COVID-19 self-test kits, left an operating profit of KRW 203.2 billion out of KRW 326.4 billion in sales in the first quarter. The operating profit margin reached 62.2%.

Seegene also achieved an operating profit of nearly KRW 200 billion with KRW 199.7 billion during the same period. Of the KRW 451.5 billion in sales, 44.2% were left as operating profit.

Moreover, Samsung Biologics recorded an operating profit margin of 34.5% with an operating profit of KRW 176.4 billion, and Celltrion had an operating profit of KRW 142.3 billion, which reached 25.8%.

Daewoong, a holding company, followed with KRW 47.1 billion, in vitro diagnostic company Sugentech with KRW 44.7 billion, and GC Pharma and Hanmi Pharmaceutical with KRW 41.8 billion and KRW 40.9 billion.

Chong Kun Dang Pharmaceutical achieved more than KRW 20 billion in operating profit with KRW 25.1 billion, Hugel with KRW 25 billion, SK Bioscience with KRW 23.8 billion, DongKook Pharmaceutical with KRW 23.4 billion, Daewoong Pharmaceutical with KRW 23 billion, and Huons Global with KRW 20.7 billion.

In the meantime, the operating profit of Kolmar BNH, Boryung Pharmaceutical, Genolution, Pharma Research Products, Genomictree, Daewon Pharmaceutical, JW Pharmaceutical, Huons, Korea United Pharmaceutical, Il-Yang Pharmaceutical, and Bioneer exceeded KRW 10 billion. 


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.